ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $621,676 | +42.7% | 6,639 | +36.0% | 0.00% | – |
| Q2 2023 | $435,719 | +11.7% | 4,882 | +34.2% | 0.00% | – |
| Q1 2023 | $390,066 | -8.8% | 3,638 | +3.9% | 0.00% | – |
| Q4 2022 | $427,821 | +28.5% | 3,503 | +8.6% | 0.00% | – |
| Q3 2022 | $333,000 | +14.8% | 3,226 | +3.4% | 0.00% | – |
| Q2 2022 | $290,000 | +9.8% | 3,121 | +39.0% | 0.00% | – |
| Q1 2022 | $264,000 | 0.0% | 2,246 | +14.4% | 0.00% | – |
| Q4 2021 | $264,000 | -83.3% | 1,964 | -80.2% | 0.00% | -100.0% |
| Q3 2021 | $1,582,000 | +23.5% | 9,927 | +2.0% | 0.00% | 0.0% |
| Q2 2021 | $1,281,000 | +10.2% | 9,734 | +7.9% | 0.00% | 0.0% |
| Q1 2021 | $1,162,000 | -54.2% | 9,020 | -40.7% | 0.00% | -50.0% |
| Q4 2020 | $2,538,000 | -0.2% | 15,220 | -7.6% | 0.00% | 0.0% |
| Q3 2020 | $2,542,000 | -23.8% | 16,475 | -26.9% | 0.00% | -33.3% |
| Q2 2020 | $3,334,000 | – | 22,541 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |